Recombinant Rhesus Macaque CD79B(Ala30-Asp161) Protein, C-6*His-tagged

• Cat.No.: CD79B-750R
• Product Overview: Recombinant Rhesus Macaque CD79B(H9ZFT8)(Ala30-Asp161) Protein, fused with a 6*His tag at the C-terminus, was produced in HEK293.

Specification

• Source: HEK293
• Species: Rhesus Macaque
• Tag: His
• Form: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
• Molecular Mass: The recombinant Rhesus Macaque CD79B Protein has a predicted molecular mass of 16.1kDa, it migrates with an apparent molecular mass of 20-30kDa under reducing conditions.
• AA Sequence: Ala30-Asp161
• Endotoxin: < 0.01 EU per μg of the protein as determined by the LAL method.
• Purity: Greater than 95% as determined by reducing SDS-PAGE.
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.25 mg/ml. Centrifuge the vial at 4°C before opening to recover the entire contents.
• Shipping: In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
  Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
• Protein length: Ala30-Asp161
• Official Symbol: CD79B
• Synonyms: B-Cell Antigen Receptor Complex-Associated Protein Beta Chain; B-Cell-Specific Glycoprotein B29; Ig-Beta; Immunoglobulin-Associated B29 Protein; CD79b; CD79B; B29; IGB

Gene Information

• Official Symbol: CD79B
• Synonyms: B-Cell Antigen Receptor Complex-Associated Protein Beta Chain; B-Cell-Specific Glycoprotein B29; Ig-Beta; Immunoglobulin-Associated B29 Protein; CD79b; CD79B; B29; IGB

Reviews

04/26/2023

Renowned for its reliability and consistency, this protein offers researchers the confidence to achieve accurate and reproducible results in their studies.

11/16/2021

The CD79B protein comes highly recommended for its outstanding performance in ELISA assays.

10/26/2018

One notable advantage of the CD79B protein is the excellent technical support provided by its manufacturer.

Q&As

How does CD79B-targeted immunotherapy differ from traditional chemotherapy in treating B cell malignancies?

CD79B-targeted immunotherapy aims to specifically target B cells, potentially reducing side effects compared to non-specific chemotherapy.

How does CD79B contribute to the development of personalized treatment strategies for B cell diseases?

Analyzing CD79B expression helps tailor treatment plans, allowing for more personalized and effective approaches.

Can CD79B be used as a biomarker for minimal residual disease in B cell malignancies?

Yes, monitoring CD79B levels can aid in detecting minimal residual disease, providing insights into treatment response.

Are there any challenges or limitations associated with relying on CD79B as a diagnostic marker?

Variability in CD79B expression among different B cell disorders may pose challenges in its use as a standalone diagnostic marker.

Are there any clinical trials investigating the therapeutic potential of CD79B-targeted drugs?

Yes, several clinical trials are exploring the efficacy of CD79B-targeted drugs in various B cell disorders.